sodium-glucose cotransporter 2 inhibitors protect against DKD by suppressing excessive glucose influx into the proximal tubular epithelial cells, which possibly involves PKM2 (28, 29) given its role in abnormal glucose metabolism. This evidence concerns the gene PKM and diabetic kidney disease.